<DOC>
	<DOCNO>NCT02722265</DOCNO>
	<brief_summary>To examine antihypertensive effect , pharmacodynamics , safety long-term administration CS-3150 monotherapy combination calcium channel blocker renin-angiotensin system inhibitor patient essential hypertension .</brief_summary>
	<brief_title>Long-term Study CS-3150 Monotherapy Combination With Other Antihypertensive Drug Japanese Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Male female subject age 20 year old informed consent Subjects essential hypertension , receive antihypertensive drug receive calcium channel blocker , angiotensin convert enzyme ACE inhibitor , angiotensinII receptor blockade ARB runin period ( Sitting systolic blood pressure SBP ≥ 140 mmHg &lt; 180 mmHg , Sitting diastolic blood pressure DBP ≥ 90 mmHg &lt; 110 mmHg , mean 24hr SBP ≥ 130 DBP ≥ 80 mmHg ) Secondary hypertension malignant hypertension Diabetes mellitus albuminuria Serum potassium level &lt; 3.5 ≥ 5.1 mEq/L ( ≥ 4.8 mEq/L receive ACE inhibitor , ARB ) Reversed daynight life cycle include overnight worker estimate glomerular filtration rate eGFR &lt; 60 mL/min/1.73 m^2 .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Essential hypertension</keyword>
	<keyword>Long-term treatment</keyword>
	<keyword>Mineralocorticoid receptor antagonist</keyword>
</DOC>